GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » Cyclically Adjusted PS Ratio

ClearPoint Neuro (ClearPoint Neuro) Cyclically Adjusted PS Ratio : 3.39 (As of Apr. 30, 2024)


View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro Cyclically Adjusted PS Ratio?

As of today (2024-04-30), ClearPoint Neuro's current share price is $5.45. ClearPoint Neuro's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.61. ClearPoint Neuro's Cyclically Adjusted PS Ratio for today is 3.39.

The historical rank and industry rank for ClearPoint Neuro's Cyclically Adjusted PS Ratio or its related term are showing as below:

CLPT' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.62   Med: 4.9   Max: 10.07
Current: 3.3

During the past years, ClearPoint Neuro's highest Cyclically Adjusted PS Ratio was 10.07. The lowest was 2.62. And the median was 4.90.

CLPT's Cyclically Adjusted PS Ratio is ranked worse than
61.08% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 2.12 vs CLPT: 3.30

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ClearPoint Neuro's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.277. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.61 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


ClearPoint Neuro Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ClearPoint Neuro's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClearPoint Neuro Cyclically Adjusted PS Ratio Chart

ClearPoint Neuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 5.51 5.22 4.66 4.21

ClearPoint Neuro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.66 4.82 4.16 2.95 4.21

Competitive Comparison of ClearPoint Neuro's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, ClearPoint Neuro's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClearPoint Neuro's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's Cyclically Adjusted PS Ratio falls into.



ClearPoint Neuro Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ClearPoint Neuro's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=5.45/1.61
=3.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClearPoint Neuro's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, ClearPoint Neuro's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.277/129.4194*129.4194
=0.277

Current CPI (Dec. 2023) = 129.4194.

ClearPoint Neuro Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.561 99.695 0.728
201406 0.807 100.560 1.039
201409 0.429 100.428 0.553
201412 0.636 99.070 0.831
201503 0.540 99.621 0.702
201506 0.441 100.684 0.567
201509 0.665 100.392 0.857
201512 0.786 99.792 1.019
201603 0.608 100.470 0.783
201606 0.560 101.688 0.713
201609 0.581 101.861 0.738
201612 0.452 101.863 0.574
201703 0.554 102.862 0.697
201706 0.313 103.349 0.392
201709 0.166 104.136 0.206
201712 0.157 104.011 0.195
201803 0.151 105.290 0.186
201806 0.150 106.317 0.183
201809 0.164 106.507 0.199
201812 0.207 105.998 0.253
201903 0.224 107.251 0.270
201906 0.212 108.070 0.254
201909 0.208 108.329 0.248
201912 0.211 108.420 0.252
202003 0.202 108.902 0.240
202006 0.160 108.767 0.190
202009 0.224 109.815 0.264
202012 0.222 109.897 0.261
202103 0.214 111.754 0.248
202106 0.159 114.631 0.180
202109 0.203 115.734 0.227
202112 0.201 117.630 0.221
202203 0.212 121.301 0.226
202206 0.217 125.017 0.225
202209 0.210 125.227 0.217
202212 0.211 125.222 0.218
202303 0.221 127.348 0.225
202306 0.242 128.729 0.243
202309 0.234 129.860 0.233
202312 0.277 129.419 0.277

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ClearPoint Neuro  (NAS:CLPT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ClearPoint Neuro Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ClearPoint Neuro (ClearPoint Neuro) Business Description

Traded in Other Exchanges
N/A
Address
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.
Executives
Lynnette C Fallon director 108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau director 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra officer: Chief Operating Officer 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett director, officer: CEO and President C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall officer: GM, Biologics & Drug Delivery 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro officer: Vice President, Finance 5 MUSICK, IRVINE CA 92618
Harold A Hurwitz officer: Chief Financial Officer
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R director C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards director ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc. 10 percent owner 75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners officer: Vice President, Marketing ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103

ClearPoint Neuro (ClearPoint Neuro) Headlines

From GuruFocus

ClearPoint Neuro to Present at Upcoming Investor Conferences

By Value_Insider Value_Insider 11-09-2022

ClearPoint Neuro Announces Receipt of MDSAP Certification

By GuruFocusNews GuruFocusNews 07-02-2022

ClearPoint Neuro Announces Receipt of MDSAP Certification

By GuruFocusNews GuruFocusNews 06-22-2022